Cytonics Corporation

💣 Critical Mass Achieved. We're thrilled to share that #Cytonics has been making tremendous strides! Here's a glimpse of the exciting developments happening behind the scenes… ✅ Phase 1 Dosing Nearing Completion We’ve officially completed the first dose in our Phase 1 trial with very promising results – no adverse events reported! The final patient is set to receive their second (and last) dose this December, keeping us on track as we move closer to wrapping up this critical stage of #drugdevelopment. 🎥 Pro Athlete Power Couple & New Marketing Content Last week, we welcomed Rener and Eve Gracie (https://lnkd.in/eK7FTrWn, https://lnkd.in/eAcZGvae)  to our clinic for their APIC treatments. These sessions will be filmed for an exciting new marketing video that showcases the power of our #FDA-cleared therapy. This #MMA power couple have joined Cytonics as major investors and our brand ambassadors. We can’t wait to share the new video with you all soon! 👥 Assembling The Osteoarthritis Dream Team In line with our mission to bring groundbreaking therapies to market, we’re expanding our Medical Advisory Board. We’ve successfully recruited 5 esteemed MD and PhD advisors (who have worked on a total of ~80 #osteoarthritis clinical studies!) and are finalizing the addition of a new Director.   These individuals will be instrumental in shaping our clinical study design, enhancing our drug product strategy, and positioning Cytonics for a potential company exit. We can’t reveal all the details just yet, but trust us—this is huge! We’re preparing for a major press release that will highlight the caliber and influence of these new team members. Thank you to all of our investors for your continued support as we work to reshape the future of osteoarthritis treatment. Stay tuned for more updates—exciting things are on the horizon!

$1M offering ends tonight!

🎯 We're 75% of the Way to Revolutionizing Osteoarthritis Treatment! We have officially raised $745,931.01, bringing us three-quarters of the way to our investment goal! With only 25% of allocation left, now is your chance to be a part of a game-changing solution for osteoarthritis. 🖇 invest.cytonics.com Don't miss out on this unique opportunity to invest in a biotech company that is on the brink of transforming lives. The clock is ticking, and so is your chance to join us on this journey. 👉 Secure your stake in the future of osteoarthritis treatment before it’s too late! #Biotech #InvestInHealth #Osteoarthritis #HealthcareInnovation #StartupInvesting #Crowdfunding #BiotechInvesting #DisruptiveInnovation #InvestInTheFuture #MedicalBreakthrough #EarlyStageInvesting #HealthTech #InvestingInScience #ImpactInvesting #EquityCrowdfunding

🪙Here’s What Makes Cytonics A Standout Investment De-risked development: Cytonics a unique investment opportunity in the biotechnology sector Learn more about the investment opportunity: invest.cytonics.com Our crowdfunding campaign ends in 4 days. By now, you are familiar with our labyrinthian origin story, our mission to revolutionize regenerative medicine, and our novel therapies for osteoarthritis. We recently advanced our lead drug candidate, CYT-108, into Phase 1 human clinical trials. So far, 18 patients have been dosed and the drug appears to be safe and well-tolerated. This is the single most critical milestone in our company’s history, and we are thrilled to give you the opportunity to invest before we launch our Phase 2 clinical trial!   Here is why you should consider investing…   💵 Capital raising success: raised over $25M to date including institutional support from J&J (a 12% shareholder).   📈 Hitting our milestones: we have dosed 14 patients in our first-in-human Phase 1 clinical trial. The single most significant milestone in our company’s history!   📝 Strong IP portfolio: issued 24 US and international patents (and 5 pending) covering all three of our technologies: the APIC therapy, FACT diagnostic, and CYT-108 biopharmaceutical.   👥 Experienced leadership: management has over 100 years’ combined experience in biotech research and development. 🌟 Track record of success: FDA-approved “APIC” therapy and “FACT” diagnostic have been in the market since 2015, providing clinical and commercial proof that our core Alpha-2-Macroglobulin technology is an effective therapy for osteoarthritis. 💲 Responsible spending: 69% of investor funds are spent on Research and Development of CYT-108. This fiscal responsibility maximizes shareholder value. #biotechnology #arthritis #crowdfunding #regenerativemedicine #venturecapital

One week left to invest in this round! invest.cytonics.com

😨 Will This New Therapy Undermine Cytonics Corporation's R&D? Researchers at Northwestern have developed a novel "Bioactive Scaffold" to treat OA... is this something to worry about? We have received a tremendous amount of interest and inquiry from our investors about this new study published by researchers at Northwestern University. Led by Dr. Samuel Stupp, this research group has synthesized a bioactive "Scaffold" that physically mimics the cartilage tissue and is chemically modified to induce cartilage production by chondrocytes: https://lnkd.in/eJ7BCcP5 🔑 Key Takeaways from the Study 🧬 Innovative Scaffold Technology: The scaffold technology presented combines bioactive peptide amphiphiles with hyaluronic acid, specifically designed to support cartilage repair in mechanically active joints. This hybrid material is not only injectable but also capable of inducing chondrogenesis with a minimal dose of TGFβ-1, making it a potent competitor in the OA treatment landscape. 🐑 Preclinical Success: The study demonstrates the scaffold's ability to regenerate hyaline cartilage in load-bearing joints of sheep, a model that closely mimics human joint conditions. The ability to withstand mechanical stresses and integrate with surrounding tissues highlights its potential as a robust therapeutic option. 💼 Market: The technology in the study represents a direct competitor in the scaffold category, with a focus on regenerative outcomes. Companies developing similar injectable scaffolds, such as those involving hyaluronic acid, peptide amphiphiles, or collagen, may pose competition, particularly as these technologies advance toward clinical trials. 🔍 Competitive Threat Or Collaborative Opportunity? 🛡️ Uniquely Positioned: While the scaffold technology presented in the study offers a promising competitive edge in cartilage regeneration, CYT-108 maintains a unique positioning through its mechanism of action and existing clinical support. CYT-108 is positioned as a novel biologic therapy, which could complement or compete with scaffold-based therapies. Its primary advantage lies in the de-risked nature of A2M-based treatments, supported by clinical data from similar therapies. 🤝 Complementary Mechanisms of Action: CYT-108 could be marketed as a synergistic treatment alongside scaffold technologies, addressing both the degradation and regeneration aspects of OA. Exploring partnerships or collaborations with companies developing scaffold technologies could strengthen CYT-108’s market position. The scaffolding technology is still in the preclinical stage, so monitoring advancements in scaffold-based therapies as they reach clinical trials will be crucial to anticipating shifts in the competitive landscape and potential threats. 📅 FYI - Our campaign ENDS on Aug 25th @ 11:59pm EST / Aug 26th @ 2:59am EST. Invest NOW: invest.cytonics.com #biotechnology #drugdevelopment #arthritis #regenerativemedicine #crowdfunding #investing

❗  REMINDER Don't Miss Our FINAL Investor Webinar with President & CEO, Joey Bose August 23, 2024 @ 4:00 PM ET 🌐 https://lnkd.in/esMEZRzH 🌟 This webinar is an excellent opportunity for you to ask questions, engage directly with our leadership, and learn more about how your investment is helping to shape the future of osteoarthritis treatment!   📅 On the Agenda 🌐 Cytonics' Journey From Startup to Disruptor: Our CEO, Joey Bose, will guide you through our remarkable evolution since 2006, highlighting our ascent to a pivotal role in osteoarthritis therapy development. Discover the milestones and challenges of our journey towards introducing CYT-108, our innovative solution poised to revolutionize osteoarthritis treatment. 💡 Breakthroughs in Drug Development: Gain an in-depth understanding of the complexities and triumphs in the path to FDA approval. Joey will shed light on the obstacles faced by biotech firms and the strategies employed by Cytonics to navigate these challenges effectively. 💰 Investing to Fuel the Future of Medicine: Delve into the intricacies of biotech financing, with a focus on how Cytonics utilizes investment capital to drive forward our mission. Learn about the impact of your investment on our progress and the broader field of regenerative medicine. ❓ Questions & Answers (30 min): This is your chance to engage directly with our team. Bring your queries about biotechnology, our R&D processes, investment strategies, or anything else you're curious about.   ❗Closing Soon Campaign Ends August 25 at 11:59pm PST / August 26th at 2:59am EST 🖇 invest.cytonics.com #biotechnology #CEO #crowdfunding #venturecapital #investing #drugdevelopment